What C.Diff. active immunotherapy program???
With no revenues to speak of the only way they're going to raise capital is with another PP imo... if they develop a cdiff immunotherapy program it might help, but that's a big if.
The latest news is that they'd started "method development" for a program....so the actual program itself is safe harbor protected if it doesn't happen.
Their PRs are long on hyperbole (meaningless words made to sound meaningful) but short of details. They talk of "outside contract manufacturers"....NAMES???
Given their cash burn and tiny revenues...I dunno. If it wasn't for all the toutsheets and email blasts going out SBOTF would still be trading around 40 cents imo.
FWIW I was in BLU.TO until very recently, a biotech that didn't get the tar kicked outta it. Look for value, not otcbb hype.
If you want to taste the fruit, you have to go out on a limb. But if you wait for the herd to move out on the limb....the branch tends to snap.